This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antonio Lee, Ph.D.
Global Head, Business Development, MEDIPOST, Korea & CEO at MEDIPOST America, USA


Dr. Antonio (Tony) Lee is the Global Head of Business Development at MEDIPOST (KOSDAQ: 078160; Seoul, Korea) and also serves as the CEO and Managing Director at MEDIPOST America Inc., a wholly-owned U.S. subsidiary of MEDIPOST.

Since 2011, Dr Lee has been involved in the global commercialization and clinical development strategy, regulatory affairs and marketing of human Umbilical Cord Blood (hUCB)-derived Stem Cell technology and products developed by MEDIPOST, including the World’s First regulatory-approved allogeneic stem cell product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA).

Dr. Lee also serves on the Board of Directors for MEDIPOST’s North Asian Joint-Venture entities – ‘ORLIFE Pharmaceuticals, Shandong, China’ and ‘EVASTEM Therapeutics, Tokyo, Japan’

Agenda Sessions

  • Chairperson’s Opening Remarks

  • Allogeneic Cord Blood-derived Cell Therapy Product CARTISTEM® for Osteoarthritis: Post-Market Status from Korea with Updates for Japan and the U.S.